Cancer researchers have long known that prostate cancer tends to be more common, more aggressive and more resistant to existing treatments in African Americans than in Caucasian Americans, but they’re only beginning to understand why.
In the absence of the federal funding, cancer research will be leaning on private funders. But few private funders have the freedom to ask fundamental questions—questions whose answers may not have an immediate clinical impact but can dramatically advance scientific knowledge.
